Jones Financial Companies’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Jones Financial Companies’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$914K	Buy	10,186 +2,297	+29%	+$189K	﹤0.01%	1945
2026 Q1	$596K	Buy	7,889 +1,385	+21%	+$112K	﹤0.01%	1954
2025 Q4	$534K	Buy	6,504 +1,146	+21%	+$88.7K	﹤0.01%	1495
2025 Q3	$367K	Sell	5,358 -26	-0.5%	-$1.76K	﹤0.01%	1524
2025 Q2	$347K	Buy	5,384 +2,898	+117%	+$180K	﹤0.01%	1432
2025 Q1	$159K	Buy	2,486 +171	+7%	+$11.5K	﹤0.01%	1581
2024 Q4	$154K	Buy	2,315 +801	+53%	+$55.2K	﹤0.01%	1462
2024 Q3	$106K	Buy	1,514 +677	+81%	+$46.9K	﹤0.01%	1377
2024 Q2	$54.2K	Buy	+837	New	+$53K	﹤0.01%	1227

Other funds holding PBE

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Jones Financial Companies's PBE Position: Q2 2026 in Review

Jones Financial Companies increased its Invesco Biotechnology & Genome ETF (PBE) stake by 29% in Q2 2026, buying an estimated $189K and bringing the position to 10,186 shares worth $914K. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

Jones Financial Companies first reported a position in PBE in Q2 2024 and has held it in 9 quarters since. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

Jones Financial Companies held 10,186 shares of Invesco Biotechnology & Genome ETF worth $914K as of Q2 2026.
Jones Financial Companies bought 2,297 Invesco Biotechnology & Genome ETF shares in Q2 2026, an estimated $189K.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #1945 holding.
Jones Financial Companies first reported a position in Invesco Biotechnology & Genome ETF in Q2 2024 and has held it in 9 quarters since.
105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.